Skip to main
BLFS

BioLife Solutions (BLFS) Stock Forecast & Price Target

BioLife Solutions (BLFS) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BioLife Solutions Inc has demonstrated robust financial performance, with Cell Processing revenue reaching $25.3 million, reflecting a 33% year-over-year growth, while total revenue for 3Q25 was reported at $28.1 million, indicating a 31% year-over-year increase. The company's net income for the quarter stood at $0.6 million, or $0.01 per share, surpassing previous loss estimates and marking a positive shift in financial health. Additionally, management anticipates a gross margin in the low-60% range for 2025, further strengthening the outlook by highlighting operational efficiency and a commitment to reducing net losses.

Bears say

The financial outlook for BioLife Solutions Inc remains cautious due to several inherent risks, including the potential for lower-than-projected growth in its product and service lines, difficulty in securing new customers, and fluctuations in emerging markets and foreign exchange rates. Additionally, the company's revenue guidance for FY2025 reflects a reduction of approximately $8 million related to its evo revenue, indicating challenges in achieving its anticipated growth targets, with projections now suggesting only 27-29% year-over-year growth. Furthermore, the potential for dilution risk adds another layer of uncertainty regarding the company’s financial stability and future performance.

BioLife Solutions (BLFS) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioLife Solutions and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioLife Solutions (BLFS) Forecast

Analysts have given BioLife Solutions (BLFS) a Strong Buy based on their latest research and market trends.

According to 1 analysts, BioLife Solutions (BLFS) has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioLife Solutions (BLFS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.